{"database": "lobbying", "table": "lobbying_activities", "rows": [[2026206, "7b334589-2757-4ea5-8194-3a0e82f15eb4", "Q3", "WAXMAN STRATEGIES", 401103693, "340B HEALTH", 2017, "third_quarter", "PHA", "Issues affecting the 340B drug pricing program", "HOUSE OF REPRESENTATIVES", 18750, null, 0, 0, "2017-10-17T09:12:29.677000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2026206"], "units": {}, "query_ms": 0.4859009641222656, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}